Axsome Therapeutics Appoints David Marek as Chief Commercial Officer
August 20 2019 - 6:00AM
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders, today
announced the appointment of David Marek as Chief Commercial
Officer, effective August 31, 2019. Mr. Marek joins Axsome from
Amgen, where he was Vice President, and General Manager of Amgen’s
Neuroscience business unit, and previously held executive positions
at WebMD and at Saatchi & Saatchi Healthcare Advertising.
“As our innovative CNS pipeline rapidly matures
towards four pivotal clinical trial readouts, and two potential NDA
filings and product launches, we are pleased to welcome Dave to the
Axsome team as Chief Commercial Officer,” said Herriot Tabuteau,
MD, Chief Executive Officer of Axsome. “Dave’s expertise in both
digital and traditional media, creative commercialization
strategies, value and access, and new product launches, is an
important addition to Axsome as we create and execute our
commercial plans and continue our growth into a leading CNS
biopharmaceutical company.”
At Amgen, Mr. Marek led the U.S.
commercialization strategy and launch of Aimovig™ for migraine
prevention, achieving industry-record launch performance for a
biologic. Prior to heading the Neuroscience business unit, he was
Vice President of Marketing of Amgen’s U.S. Inflammation and
Nephrology business leading it to attain over $9 billion in annual
revenue. Before Amgen, Mr. Marek served as Executive Vice
President, Consumer Services, and Commercial Strategy Officer of
WebMD, one of the largest providers of healthcare digital content,
and the top healthcare website by unique visitors. Prior to WebMD,
Mr. Marek was the Managing Director of Saatchi & Saatchi
Healthcare Advertising where he developed and implemented creative
strategies to grow many of the most successful pharmaceutical
brands. Mr. Marek began his career at Eli Lilly and Company,
followed by AstraZeneca, where he served in a variety of marketing
and sales roles of increasing responsibility. He earned his
Bachelor of Arts degree in Business Administration from Washington
State University.
“Axsome’s growing pipeline of clinically and
mechanistically differentiated, late-stage product candidates for
CNS conditions with high medical need exemplify its patient-centric
approach to innovation,” said Mr. Marek. “I am excited to join
Axsome at such a significant time as we approach multiple clinical
trial readouts later this year, and I look forward to working with
the rest of the team to bring our novel investigational medicines
to patients as expediently and as efficiently as possible.”
About Axsome Therapeutics,
Inc.
Axsome Therapeutics, Inc. is a clinical-stage
biopharmaceutical company developing novel therapies for the
management of central nervous system (CNS) disorders for which
there are limited treatment options. Axsome’s core CNS product
candidate portfolio includes four clinical-stage candidates,
AXS-05, AXS-07, AXS-09, and AXS-12. AXS-05 is currently in a Phase
3 trial in treatment resistant depression (TRD), a Phase 3 trial in
major depressive disorder (MDD), and a Phase 2/3 trial in agitation
associated with Alzheimer’s disease (AD). AXS-05 is also being
developed for smoking cessation treatment. AXS-07 is currently in a
Phase 3 trial for the acute treatment of migraine. AXS-12 is
currently in a Phase 2 trial in narcolepsy. The Axsome Pain and
Primary Care business unit (Axsome PPC) houses Axsome’s pain and
primary care assets, including AXS-02 and AXS-06, and intellectual
property which covers these and related product candidates and
molecules being developed by Axsome and others. AXS-02 is being
developed for osteoporosis, the pain of knee osteoarthritis, and
chronic low back pain. AXS-06 is being developed for osteoarthritis
and rheumatoid arthritis. AXS-02, AXS-05, AXS-06, AXS-07, AXS-09,
and AXS-12 are investigational drug products not approved by the
FDA. For more information, please visit the Company’s website at
axsome.com. The Company may occasionally disseminate material,
nonpublic information on the company website.
Forward Looking Statements
Certain matters discussed in this press release
are “forward-looking statements”. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. In particular, the Company’s statements
regarding trends and potential future results are examples of such
forward-looking statements. The forward-looking statements include
risks and uncertainties, including, but not limited to, the
success, timing and cost of our ongoing clinical trials and
anticipated clinical trials for our current product candidates,
including statements regarding the timing of initiation, pace of
enrollment and completion of the trials (including our ability to
fully fund our disclosed clinical trials, which assumes no material
changes to our currently projected expenses), futility analyses and
receipt of interim results, which are not necessarily indicative of
the final results of our ongoing clinical trials, and the number or
type of studies or nature of results necessary to support the
filing of a new drug application (“NDA”) for any of our current
product candidates; our ability to fund additional clinical trials
to continue the advancement of our product candidates; the timing
of and our ability to obtain and maintain U.S. Food and Drug
Administration (“FDA”) or other regulatory authority approval of,
or other action with respect to, our product candidates (including,
but not limited to, FDA’s agreement with the Company’s plan to
discontinue the bupropion treatment arm of the ADVANCE-1 study in
accordance with the independent data monitoring committee’s
recommendations); the potential for the ASCEND clinical trial to
provide a basis for approval of AXS-05 for the treatment of major
depressive disorder and accelerate its development timeline and
commercial path to patients; the Company’s ability to successfully
defend its intellectual property or obtain the necessary licenses
at a cost acceptable to the Company, if at all; the successful
implementation of the Company’s research and development programs
and collaborations; the success of the Company’s license
agreements; the acceptance by the market of the Company’s product
candidates, if approved; the Company’s anticipated capital
requirements, including the Company’s anticipated cash runway and
the Company’s current expectations regarding its plans for future
equity financings prior to the readout from its Phase 3 trials; and
other factors, including general economic conditions and regulatory
developments, not within the Company’s control. The factors
discussed herein could cause actual results and developments to be
materially different from those expressed in or implied by such
statements. The forward-looking statements are made only as of the
date of this press release and the Company undertakes no obligation
to publicly update such forward-looking statements to reflect
subsequent events or circumstance.
Axsome Contact: Mark Jacobson Senior Vice
President, Operations Axsome Therapeutics, Inc. 200 Broadway, 3rd
Floor New York, NY 10038 Tel: 212-332-3243 Email:
mjacobson@axsome.comwww.axsome.com
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From Apr 2024 to May 2024
Axsome Therapeutics (NASDAQ:AXSM)
Historical Stock Chart
From May 2023 to May 2024